Keryx Offers Phase 2 Trial Results for Auryxia in NDD-CKD Patients

Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX), a biopharmaceutical company focused on bringing innovativetherapies to market for patients with renal disease, today announced thepublication of Auryxia phase 2 clinical trial results in non-dialysisdependent chronic kidney disease (NDD-CKD) patients in the American Journal ofKidney Diseases (AJKD). Based on the results of this study, in September 2014,the Company initiated a Phase 3 pivotal program of Auryxia as a treatment foriron-deficiency anemia in patients with Stages 3-5 NDD-CKD.The study's Co-Chairmen were Geoffrey Block, MD, Director of Clinical Researchat Denver Nephrology; Glenn Chertow, MD, Professor of Medicine and Chief,Division of Nephrology at Stanford University School of Medicine; and StevenFishbane, MD, Division Chief, Kidney Disease and Hypertension at North ShoreUniversity Hospital/Long Island Jewish Medical Center.Dr. Block commented, "Iron deficiency anemia is very common in chronic kidneydisease stages 3 to 5, with more than 1.5 million Americans estimated to beimpacted by this condition. Currently, there are no good treatment options forpatients as conventional oral iron formulations are poorly absorbed and notwell tolerated. The results of this study support further evaluation ofAuryxia for the treatment of iron deficiency anemia in this patientpopulation."